Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit have increased, the company faces geographical and client concentration risks. Despite a high P/E ratio compared to peers, investors with a high-risk (...)
Site référencé: The Economic Times
The Economic Times
BEML shares trade 2% higher on stock split hopes ahead of board meet
14/07/2025
JP Power shares rally 7% in one week. Should you buy, sell or hold ?
14/07/2025
IPO Spotlight : 7 IPOs in focus this week ; 4 new issues to open, 3 listings on radar
14/07/2025
Life insurance sector in good health : Siddhartha Khemka prefers HDFC Life, SBI Life on margin gains
14/07/2025
The Golden Thumbrule : Is it time to exit ? Aniruddha Sarkar’s playbook for spotting sector wear and tear
14/07/2025
Ola Electric to announce Q1FY26 results today. Here’s what to expect
14/07/2025
